Literature DB >> 10336835

Therapeutic strategies to reduce TNF-alpha mediated cardiac contractile depression following ischemia and reperfusion.

B S Cain1, A H Harken, D R Meldrum.   

Abstract

Recent evidence has implicated proinflammatory mediators such as TNF- alpha in the pathophysiology of ischemia-reperfusion (I/R) injury. Clinically, serum levels of TNF-alpha are increased after myocardial infarction and after cardiopulmonary bypass. Each of these represent clinically relevant instances of cardiac I/R injury. We and others have recently reported that TNF-alpha is produced by the heart following experimental I/R in animals and that TNF-alpha directly decreases animal and human myocardial contractility in a dose dependent fashion. Thus, strategies to reduce or neutralize myocardial TNF- alpha production should conceptually decrease myocardial contractile dysfunction following I/R. The purposes of this manuscript are: 1) to explore the clinical and experimental instances of I/R injury in which TNF-alpha is elevated, 2) to review the molecular mechanisms of TNF- alpha induced contractile dysfunction, 3) to examine both experimental and clinical strategies of reducing myocardial TNF-alpha production, and 4) to determine the influence of reducing post-I/R TNF-alpha on cardiac contractile function in both animals and man. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10336835     DOI: 10.1006/jmcc.1999.0924

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  12 in total

Review 1.  Membrane raft redox signalosomes in endothelial cells.

Authors:  Chun Zhang; Pin-Lan Li
Journal:  Free Radic Res       Date:  2010-08

Review 2.  Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction.

Authors:  U N Das
Journal:  Mol Cell Biochem       Date:  2000-12       Impact factor: 3.396

3.  Adenosine postconditioning protects against myocardial ischemia-reperfusion injury though modulate production of TNF-α and prevents activation of transcription factor NF-kappaB.

Authors:  Jian-Juan Ke; Feng-Xu Yu; Yan Rao; Yan-Lin Wang
Journal:  Mol Biol Rep       Date:  2010-04-09       Impact factor: 2.316

4.  A novel function of insulin in rat dermis.

Authors:  Torbjørn Nedrebø; Tine V Karlsen; Gerd S Salvesen; Rolf K Reed
Journal:  J Physiol       Date:  2004-07-02       Impact factor: 5.182

5.  Role of tumour necrosis factor-alpha and other cytokines in ischemia-reperfusion-induced injury in the heart.

Authors:  Harjot K Saini; Yan-Jun Xu; Ming Zhang; Peter P Liu; Lorrie A Kirshenbaum; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2005

6.  Ulinastatin attenuates protamine-induced cardiotoxicity in rats by inhibiting tumor necrosis factor alpha.

Authors:  Hisashi Fukushima; Takeshi Oguchi; Hiroaki Sato; Yosuke Nakadate; Tamaki Sato; Keisuke Omiya; Akiko Kawakami; Toru Matsuoka; Takashi Matsukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-08       Impact factor: 3.000

7.  Regulation of monocyte induced cell migration by the RNA binding protein, FXR1.

Authors:  O Le Tonqueze; S Kollu; S Lee; M Al-Salah; S S Truesdell; S Vasudevan
Journal:  Cell Cycle       Date:  2016-05-26       Impact factor: 4.534

8.  Inhibition of TNF-alpha induced cell death in human umbilical vein endothelial cells and Jurkat cells by protocatechuic acid.

Authors:  J Zhou-Stache; R Buettner; G Artmann; C Mittermayer; A K Bosserhoff
Journal:  Med Biol Eng Comput       Date:  2002-11       Impact factor: 2.602

9.  M3 subtype of muscarinic acetylcholine receptor promotes cardioprotection via the suppression of miR-376b-5p.

Authors:  Zhenyu Pan; Yueping Guo; Hanping Qi; Kai Fan; Shu Wang; Hua Zhao; Yuhua Fan; Jing Xie; Feng Guo; Yunlong Hou; Ning Wang; Rong Huo; Yong Zhang; Yan Liu; Zhimin Du
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240

Review 10.  Is insulin an endogenous cardioprotector?

Authors:  Undurti N Das
Journal:  Crit Care       Date:  2002-07-31       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.